Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

類似資料

• Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
  著者:: Bel, E, 等
  出版事項: (2014)
• Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
  著者:: Shrimanker, R, 等
  出版事項: (2018)
• Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
  著者:: Prazma CM, 等
  出版事項: (2021-06-01)
• Mepolizumab for eosinophilic COPD
  著者:: Sciurba, F, 等
  出版事項: (2018)
• Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
  著者:: Charlene M. Prazma, 等
  出版事項: (2019-05-01)